Brief: UroGen Reports 72.2% 24-Month Response in Phase 3 Trial of FDA-Approved Zusduri
05/08/2025 14:08
Aug 5 (Reuters) - Urogen Pharma Ltd UR8.F: UROGEN ANNOUNCES 24-MONTH DURATION OF RESPONSE OF 72.2% FROM THE PIVOTAL PHASE 3 ENVISION TRIAL OF ZUSDURI, THE FIRST AND ONLY FDA-APPROVED MEDICINE FOR RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER UROGEN PHARMA LTD - SERIOUS ADVERSE REACTIONS OCCURRED IN 12% OF PATIENTS Source text: ID:nGNX6V0G2 Further company coverage: UR8.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors